We have with us superior qualityBACLOFEN TABSwhich are well known among our customers for their high efficiency and negligible side effects. Our offered medicines are primarily used as treatment under doctors guidance in various hospitals and clinics. We procure these medicines from trustworthy vendors, which makes them pure and precisely formulated.
Mehadia Tradelinks is the leading exporter of pharmaceutical products and medicines in India.We provide the best quality medicines and quick services for all customers around the globe with all necessary tracking information of the products.We are a specialist in BACLOFEN TABS
We have strong global networks in AFRICA, Europe, United Kingdom, China, Japan, Russia, Ukraine, Dubai, Unites Arab Emirates, Thailand, Vietnam, Middle East and South East Countries.
Destination | Delivery Time |
India | 24-48 Hours |
China / Hong Kong / Singapore/ Malaysia/Myanmar | Within 4-5 Working Days |
Vietnam / Philippines / Indonesia | Within 6 Working Days |
Uk / Usa / Europe / South America / Uae / Canada / Australia/Sudan/South Sudan/Djibouti/Uganda/Somalia/Yemen/Oman/Ethiopia/Juba/Chad | Within 7 Working Days |
All countries
Yes
Additional information about medicines
No
Guarantee
Prescription and non-prescription
Order by mail
By phone
We will send a 2nd item (2 tablets and 4gm) to your email and you will get a 3rd item (3 tablets and 2gm) as soon as you place your order. Otherwise, you will still receive this item by your doorstep. An extra charge is usually included for every order. An extra twist or cut the medicine is used for splitting it in half. The medicines are to be taken with water, preferably within 4-5 days.Please note that this item is for adults only and not suitable for children.
Your email addressLeodstock_mehadia_tradock_mehadia_mehadia_mehadia_tradock_mehadia_mehadia_tradock_mehadia_mehadia_tradock_mehadia_tradock_mehadia_mehadia_tradock_nutrition_mehadia_nutrition_mehadia_nutrition_mehadia_nutrition_mehadia_nutrition_mehadia_nutrition_mehadia_nutrition_nutrition_mehadia_nutrition_nutrition_mehadia_nutrition_nutrition_nutrition_no5555771678awaitedmechanismIngredients
Each film-coated tablet contains Baclofen (the active ingredient) 30 mg.
Baclofen film-coated tablet 30 mg Baclofen film-coated tablet film-coated tabletsDirections
Take this medicine with at least one full glass of water.
Baclofen, a medication primarily used to treat muscle spasms caused by neurological conditions such as multiple sclerosis, spinal cord injuries, and other neurological disorders, is experiencing significant growth in the global pharmaceutical market. Here’s a comprehensive analysis of the baclofen market, including its current state, future projections, and key drivers.
As of 2024, the global baclofen market was valued at approximately USD 16,524.27 million. It is projected to grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2034, reaching a market size of USD 30,976.43 million by 2034[1].
The market is represented by:
The rising incidence of neurological disorders such as multiple sclerosis and spinal cord injuries and the importance of managing them--------is a major driver of the baclofen market. The prevalence of these conditions can lead to a higher demand for baclofen[1].
To reduce the burden of these conditions on individual patients, increased awareness and Destigmatization of neurological disorders--------can significantly impact the market. The introduction of new disorders and the adoption of new medications--------have led to a change in the attitude of patientsentallycare patients in the market[1].
The efficacy and market share of baclofen are influenced by several key factors:
Baclofen, containing sildenafil, is not considered a reliable medication for the treatment of neurological disorders. Regulatory considerations and cost-hester societyospanservices*****utral counselling are the main challenges faced by patientsentallycare patients in the market. Regulatory uncertainties and the growing stigma that results from hesitancy are also factors that can restrain its market share[1].
Patientsentallycare patients have to comply with various regulatory requirements and be mindful of the importance of sign-up before they request a refill. Compliance with these requirements helps in reducing the time lost from work and making sure that the medication reaches the correct dose and duration for the patient[1].
The price hike of baclofen can hurt the market by increasing the price for generic medications. Regulatory initiatives such as theettle price tag and a higher price for branded products are some examples of these factors[1].
Baclofen is a non-steroidal anti-inflammatory drug (NSAID) widely used for the treatment of spasticity and muscle spasms caused by various neurological disorders. Its mechanism of action involves binding to and inhibiting the enzyme responsible for the production of muscle acetylcholine (ACh). Baclofen is a muscle-specific inhibitor that is used to treat spasticity associated with multiple sclerosis (MS) and other neurological disorders. The effectiveness of baclofen can vary from person to person, and the risk of adverse effects is believed to be related to individual response to treatment.
Spasticity is a common neurological disorder that affects multiple organs and is often seen in people with multiple sclerosis and spinal cord diseases. Neurologists sometimes refer to spasticity as spasticity is an “abnormal” muscle tone, or “spasm of the muscles,” or “muscle spasm.” In this condition, spasticity causes weakness and spasms of the muscles. Muscle spasms are typically short-lived and typically resolve with rest or movement. However, if the symptoms persist for a long time, the person may be given the option of muscle relaxants, and the patient may receive a different medication.
A recent study reported a significant increase in risk of adverse effects of baclofen for people with spasticity. However, it was unclear if this risk increased with longer treatment periods. There is currently no consensus about whether the risk of baclofen-associated muscle spasms is greater with longer treatment periods. Therefore, the study was conducted to assess the risk of baclofen-associated muscle spasms in people with spasticity treated for up to six months. It was hypothesized that treatment with baclofen would increase the risk of muscle spasms for people with spasticity treated for up to six months.
Materials and Methods
A community-based cohort study was conducted from May 2019 to June 2020. Participants were recruited via advertisements in the online health services market. These advertisements included advertisements of “treating spasticity” and “muscle spasms”. Individuals were aged 18 years and above, and their medical records were reviewed to collect demographic information, diagnosis, medication use, and treatment history. The participants were included in the study if they had a diagnosis of spasticity with at least one muscle disorder, spinal cord diseases, or a spinal cord injury. Those with an estimated disability due to spasticity were excluded from the study. Patients who had received baclofen had to meet the following criteria: (1) were diagnosed with spasticity (tension, spasm, muscle spasm), (2) were treated with a muscle relaxant or spasm reducer, and (3) had at least one muscle disorder (spasticity, spasm, muscle spasm), spinal cord diseases, or a spinal cord injury.
Participants were excluded from the study if they had a diagnosis of spinal cord diseases, had a spinal cord injury or a spinal cord diseases, had a diagnosis of cerebral palsy, or had received any other type of surgery. Those with a spinal cord injury had to meet the following criteria: (1) were diagnosed with a spinal cord disease, spinal cord diseases, or cerebral palsy, and (2) were treated with muscle relaxants or spasm reducers. Those with a spinal cord injury had to meet the following criteria: (1) were treated with a muscle relaxant or spasm reducer, and (2) had a diagnosis of cerebral palsy or a spinal cord injury. Those with a diagnosis of cerebral palsy had to meet the following criteria: (1) were treated with a muscle relaxant or spasm reducer, and (2) had a spinal cord injury. Those with a diagnosis of spinal cord diseases had to meet the following criteria: (1) were treated with a muscle relaxant or spasm reducer, and (2) had a spinal cord injury.
Participants were also excluded if they were under 18 years of age, had a diagnosis of multiple sclerosis, had a diagnosis of cerebral palsy, were treated with a muscle relaxant or spasm reducer, or had a diagnosis of spasticity (including spasm, pain, numbness, or weakness, and at least one muscle disorder).
Participants were included in the study if they were diagnosed with spasticity with at least one muscle disorder, spinal cord diseases, or a spinal cord injury, and were treated with a muscle relaxant or spasm reducer.
Baclofen Tablets 10 mg by Teva a muscle relaxer and an antispastic agent. Baclofen is used to treat muscle symptoms caused by multiple sclerosis, including spasm, pain, and stiffness. Baclofen may also be used for purposes not listed in this medication guide.
Each tablet, for oral administration, contains 10 mg baclofen. In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, pregelatinized starch, colloidal silicon dioxide, and magnesium stearate.
Baclofen tablets 10 mg are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets 10 mg are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.
The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions.
A significant number of patients in clinical studies have reported improvement in illness symptoms with baclofen treatment.
This work was supported by the following grants:
P. I. M. was supported by a PhD scholarship from the Wellcome Trust.
D. K. was supported by the National Institutes of Health (grant number HD083430). J. was supported by a PhD scholarship from the National Institute of Mental Health.
and M. F. were supported by a postdoctoral fellowship from the University of Pittsburgh. is currently an investigator in the Institute of Chemical Engineering and Biochemistry (IECB) at the University of Pittsburgh and a PhD student in the Department of Chemistry at the University of Colorado. is currently an investigator in the Institute of Chemical Engineering and Biochemistry (IECB) at the University of Colorado (Cochrane Database on Mental Disorders, Version 2, 2018, version 9).
and J. were supported by the National Institutes of Health (grant number HD083430).
L. B., D. are employees of AstraZeneca, Inc.
Citation: L. (2019, May 23) Baclofen: A Reference Guide for the Reference to the National Library of Medicine's Reference to Baclofen, Version 1. https://medicalxpress.com/news/2019-05-baclofen- Reference Guide. (2019, May 23) Baclofen: A Reference Guide to the Reference to Baclofen, Version 1.
Stade de France Pharmacy